RAC 0.28% $1.78 race oncology ltd

RAC Charts, page-642

  1. 1,683 Posts.
    lightbulb Created with Sketch. 330
    Bad choice of words from me. Sorry

    I just don't think most investors comprehend the potential of Bisantrene. After the new five path strategy, I started reading up on the term/concept of MRD. I was just so surprised to find that in most cancers (but mostly blood cancers) it was still a rather big hurdle block.

    So Bisantrene got me more excited than CAR-T treatments.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.